We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+14.73%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$352M
AUM Growth
+$80.2M
Cap. Flow
+$76.6M
Cap. Flow %
21.79%
Top 10 Hldgs %
34.86%
Holding
100
New
24
Increased
44
Reduced
21
Closed
11

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$14M
2
LLY icon
Eli Lilly
LLY
+$11.2M
3
EW icon
Edwards Lifesciences
EW
+$7.88M
4
HAE icon
Haemonetics
HAE
+$6.52M
5
CVS icon
CVS Health
CVS
+$6.34M

Top Sells

Rank Stock Value
1
IRTC icon
iRhythm Holdings
IRTC
+$7.01M
2
ALT icon
Altimmune
ALT
+$6.55M
3
AVTR icon
Avantor
AVTR
+$5.36M
4
MASS icon
908 Devices
MASS
+$3.07M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$2.59M

Sector Composition

Rank Sector Weight
1 Healthcare 96.37%
2 Industrials 1.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
51
DELISTED
Arcellx
ACLX
$2.63M 0.75%
139,875
-38,125
-21% -$730K
AXGN icon
52
Axogen
AXGN
$2.67B
$2.38M 0.68%
200,000
+11,506
+6% +$115K
ALNY icon
53
Alnylam Pharmaceuticals
ALNY
$30B
$2.18M 0.62%
10,873
-9,861
-48% -$1.88M
IMUX icon
54
Immunic
IMUX
$217M
$2.08M 0.59%
65,764
+761
+1% +$31.9K
RXST icon
55
RxSight
RXST
$294M
$2M 0.57%
166,761
+51,761
+45% +$711K
ESPR
56
DELISTED
Esperion Therapeutics
ESPR
$1.99M 0.56%
+296,381
New +$2.04M
FULC icon
57
Fulcrum Therapeutics
FULC
$284M
$1.9M 0.54%
235,385
-27,304
-10% -$195K
AKYA
58
DELISTED
Akoya BioSciences
AKYA
$1.9M 0.54%
161,701
-23,084
-12% -$304K
BCYC
59
Bicycle Therapeutics
BCYC
$284M
$1.89M 0.54%
81,364
+20,938
+35% +$498K
PHLT
60
DELISTED
Performant Healthcare Inc
PHLT
$1.89M 0.54%
1,023,350
+12,026
+1% +$28K
LFCR icon
61
Lifecore Biomedical
LFCR
$181M
$1.8M 0.51%
202,248
+80,630
+66% +$820K
TMDX icon
62
Transmedics
TMDX
$3.02B
$1.77M 0.5%
+42,358
New +$1.84M
XFOR icon
63
X4 Pharmaceuticals
XFOR
$425M
$1.63M 0.46%
+31,667
New +$1.09M
KNSA icon
64
Kiniksa Pharmaceuticals
KNSA
$6.1B
$1.62M 0.46%
126,192
+1,484
+1% +$16.9K
KRMD icon
65
KORU Medical Systems
KRMD
$152M
$1.52M 0.43%
683,466
+8,032
+1% +$19.9K
MDGL icon
66
Madrigal Pharmaceuticals
MDGL
$12.4B
$1.4M 0.4%
21,590
+254
+1% +$17.6K
LQDA icon
67
Liquidia Corp
LQDA
$7.01B
$1.38M 0.39%
+254,452
New +$1.43M
ETNB
68
DELISTED
89bio
ETNB
$1.3M 0.37%
+225,000
New +$989K
SLN
69
Silence Therapeutics
SLN
$641M
$1.28M 0.36%
127,458
+101,208
+386% +$1.07M
VCYT icon
70
Veracyte
VCYT
$3.59B
$1.01M 0.29%
60,883
-13,083
-18% -$294K
XAIR icon
71
Beyond Air
XAIR
$5.37M
$941K 0.27%
+316
New +$1.19M
TELA icon
72
TELA Bio
TELA
$32.3M
$940K 0.27%
110,280
+1,296
+1% +$10.7K
PEPG icon
73
PepGen
PEPG
$201M
$908K 0.26%
+100,000
New +$983K
ISEE
74
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$897K 0.26%
+50,000
New +$656K
MIRM icon
75
Mirum Pharmaceuticals
MIRM
$6.04B
$891K 0.25%
42,395
+10,381
+32% +$250K
1 2
3
4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2022 Portfolio in Review

As of Q3 2022, Parkman Healthcare Partners held 100 positions worth $352M, up 30% from $272M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Parkman Healthcare Partners deployed $76.6M of net new capital in Q3 2022, opening 24 new positions and adding to 44 existing holdings. Its largest new stake was Boston Scientific: 347,787 shares worth $13.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was iRhythm Holdings, an estimated $7.01M trimmed.

  • Parkman Healthcare Partners's largest Q3 2022 buy was Boston Scientific: 347,787 shares worth $13.5M.
  • Parkman Healthcare Partners added most to Haemonetics in Q3 2022, an estimated $6.52M increase.
  • Parkman Healthcare Partners's biggest Q3 2022 reduction was iRhythm Holdings, cutting an estimated $7.01M.
  • Parkman Healthcare Partners fully exited Altimmune in Q3 2022, selling an estimated $6.55M.
  • Parkman Healthcare Partners's ten largest holdings make up 35% of its $352M portfolio in Q3 2022.
  • Parkman Healthcare Partners opened 24 new positions and closed 11 in Q3 2022.
  • Parkman Healthcare Partners's portfolio value rose 30% quarter-over-quarter to $352M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2022, filed 14 Nov 2022.